ALK and non-small cell lung carcinoma: However, exceptions from this rule are possible, for example the rapid and widespread use of stereotactic radiotherapy for stage I NSCLC or approval of crizotinib in patients with rearrangements of anaplastic lymphoma kinase (ALK) gene.